Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 3Head & Neck 3Gynecologic 3Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Vomiting 2Breast Neoplasms 2Nausea 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × fosaprepitant × Breast × Clear all
NCT05841849 2023-05-03

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Not yet recruiting
1,028 enrolled
Breast

Breast Neoplasms, Vomiting

NCT01649258 2017-11-17

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

University of Southern California

Phase 1 Terminated
29 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡